Risankizumab for children with moderate to severe Crohn's
Treatments studied
Part of Digestive system clinical trials.
This study tests a new medicine called risankizumab for children with moderate to severe Crohn's disease. It is given as an IV infusion or a shot under the skin to see if it can reduce inflammation and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is between 2 and under 18 years old.
- They have moderate to severe Crohn's disease, as shown by a special score (PCDAI > 30).
- An endoscopy shows ulcers or inflammation in the bowel (SES-CD score of 6 or more, or 4 if only the ileum is affected).
- They have tried at least one other Crohn's treatment (like steroids, aminosalicylates, immune suppressants, or biologics) and it did not help enough or caused side effects.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new targeted therapy for adults with moderate to severe Crohn's disease who haven't responded well to other treatments. It aims to reduce inflammation and improve symptoms.
This study tests advanced treatments for people with moderate to severe Crohn's disease or ulcerative colitis who haven't responded to at least one previous therapy. It aims to find better options for managing these conditions.
This study tests two oral/ injectable medicines (upadacitinib and risankizumab) in adults with moderate-to-severe Crohn's who have already tried a TNF-blocker. It aims to see how well these treatments work in everyday practice.
This study tests mirikizumab to reduce inflammation and symptoms in children with Crohn’s disease that is currently active. It may help if your Crohn’s has not improved enough (or stopped working) with at least one other Crohn’s medicine.
This Phase 3 trial tests guselkumab to treat children with moderately to severely active Crohn’s disease and ongoing inflammation in the bowel. If you qualify, the study will check whether the medicine can improve symptoms and healing, especially in children who did not respond to other treatments.
This study tests an oral pill called upadacitinib for children with moderate to severe Crohn's disease that hasn't responded well to other treatments. It aims to see if the medicine can reduce inflammation and improve symptoms safely.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.